chlorpromazine has been researched along with ajmaline in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kitagawa, H; Kobayashi, Y; Matsui, T; Mizoguchi, Y; Monna, T; Morisawa, S; Yamamoto, S | 1 |
Topliss, JG; Yoshida, F | 1 |
Amado, Mdel R; Carrillo, AK; Galarreta, BC; Maruenda, H; Sanchez, L; Sifuentes, R | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
5 other study(ies) available for chlorpromazine and ajmaline
Article | Year |
---|---|
[Studies on the drug-induced injury and changes of membrane structure in the isolated liver cells].
Topics: Ajmaline; Animals; Cell Membrane; Cell Separation; Chemical and Drug Induced Liver Injury; Chlorpromazine; In Vitro Techniques; Liver; Liver Diseases; Male; Rats; Rats, Inbred Strains | 1983 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
Topics: Animals; Biological Products; Enzyme Inhibitors; Flavins; Harmaline; Indole Alkaloids; Leishmania; NADH, NADPH Oxidoreductases; Quinolines; Trypanocidal Agents; Trypanosoma cruzi | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |